Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.
Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).
Loubière S, et al. Among authors: missy p.
Eur Respir J. 2018 Mar 15;51(3):1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.
Eur Respir J. 2018.
PMID: 29545318
Free article.